COMMITMENTS AND CONTINGENCIES (Details) (USD $)	3 Months Ended		6 Months Ended	9 Months Ended			9 Months Ended						6 Months Ended		9 Months Ended					6 Months Ended	9 Months Ended		6 Months Ended	9 Months Ended					9 Months Ended			12 Months Ended			1 Months Ended	9 Months Ended	23 Months Ended	84 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013 Access Pharmaceuticals [Member] Annual Sales, Certain Products [Member] Minimum [Member]	Sep. 30, 2013 Access Pharmaceuticals [Member] Annual Sales, Certain Products [Member] Maximum [Member]	Sep. 30, 2013 Access Pharmaceuticals [Member] Annual Sales, Any One Certain Product [Member]	Sep. 30, 2013 Access Pharmaceuticals [Member] Cumulative Sales, Certain Products [Member] Minimum [Member]	Sep. 30, 2013 Access Pharmaceuticals [Member] Cumulative Sales, Certain Products [Member] Maximum [Member]	Mar. 07, 2008 ProStrakan Ltd [Member]	Jun. 30, 2013 Kerry P. Gray [Member]		Sep. 30, 2013 Kerry P. Gray [Member]		Sep. 30, 2012 Kerry P. Gray [Member]		Dec. 31, 2012 Kerry P. Gray [Member]	Jun. 30, 2013 Terrance K. Wallberg [Member]	Sep. 30, 2013 Terrance K. Wallberg [Member]	Sep. 30, 2012 Terrance K. Wallberg [Member]	Jun. 30, 2013 Key Executives [Member]	Sep. 30, 2013 Key Executives [Member]	Sep. 30, 2012 Key Executives [Member]	Sep. 30, 2013 Altrazeal Trading Ltd. [Member]	Sep. 30, 2012 Altrazeal Trading Ltd. [Member]	Dec. 31, 2012 Altrazeal Trading Ltd. [Member]	Sep. 30, 2013 Altrazeal Trading Ltd. [Member] Sales Revenue, Goods, Net [Member]	Sep. 30, 2012 Altrazeal Trading Ltd. [Member] Sales Revenue, Goods, Net [Member]	Sep. 30, 2013 Altrazeal Trading Ltd. [Member] Accounts Receivable [Member]	Dec. 31, 2012 Altrazeal Trading Ltd. [Member] Accounts Receivable [Member]	Sep. 30, 2013 Chairman, CEO and President [Member]	Mar. 09, 2009 Chairman, CEO and President [Member]	Mar. 31, 2013 Office and Laboratory Space [Member]	Sep. 30, 2013 Office and Laboratory Space [Member]	Feb. 22, 2013 Office and Laboratory Space [Member]	Mar. 31, 2013 Office and Laboratory Space [Member]	Sep. 30, 2013 Office Equipment [Member]
Operating Leased Assets [Line Items]
Minimum monthly lease obligation																																			$ 9,128		$ 9,776	$ 9,330	$ 744
Future minimum monthly lease obligation after specified period																																				9,314
Minimum monthly lease obligation on exercise of option																																				8,751
Lease term																																				2 years
Amended lease term on exercise of option																																				5 years
Increase in minimum monthly lease obligation																																				186
Future minimum lease payments [Abstract]
2013 (Three months)	29,811			29,811
2014	120,917			120,917
2015	28,881			28,881
2016	0			0
2017	0			0
Total	179,609			179,609
Rent expense for operating lease	31,083	32,971		86,125	98,111
Employment Agreements [Abstract]
Term of employment				1 year
Renewal term				1 year
Separation Agreements [Line Items]
Total separation benefit payments																																		400,000
Period for separation benefit payments																																	48 months	12 months
Monthly separation benefits payments																																	12,500
Period for separation health coverage																																		24 months
Related Party Obligations [Abstract]
Related party sales																										143,000	22,000
Outstanding accounts receivable																										82,000		101,000
Concentration risk, percentage (in hundredths)	70.00%	48.00%		66.00%	39.00%																								59.00%	11.00%	35.00%	77.00%
Summary of compensation earned, compensation paid in cash, and compensation temporarily deferred [Abstract]
Deferred compensation liability			197,838	(55,039)	272,156								140,313	[1]	(23,500)	[1]	220,673	[1]		36,539	(11,539)	24,230	20,986	(20,000)	27,253
Deferred compensation	414,955			414,955		469,994									337,486	[1]			169,000		49,230			28,239
Deferred compensation liability pursuant to separation agreement															11,500
Deferred compensation liability pursuant to duties as chairman															157,500
Repayment of temporarily deferred compensation															192,500
Proceeds from issuance of common stock under March 2013 offering															180,000
Compensation accounts payable	275,000			275,000		310,000
Compensation accrued liabilities	139,955			139,955		159,994
Milestone payments [Line Items]
Future milestone obligations	4,750,000			4,750,000								1,400,000
Milestone for payment							$ 20,000,000	$ 40,000,000	$ 20,000,000	$ 50,000,000	$ 100,000,000
Royalty percentage (in hundredths)												30.00%

[1] During 2013, Mr. Gray temporarily deferred compensation of $169,000 which consisted of $11,500 earned pursuant to a Separation Agreement and $157,500 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors. During 2013, Mr. Gray was also repaid $192,500 of temporarily deferred compensation, of which $180,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.